1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Keros Therapeutics, Inc.

Keros Therapeutics, Inc.

KROS
Keros Therapeutics, Inc.US flagNASDAQ Global Market
11.32
USD
+0.26
- -
224.44MMarket Cap

Total Valuation

Keros Therapeutics, Inc. carries a market capitalization of 224.44M, placing it among publicly traded companies globally. Its enterprise value stands at -29.73M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap224.44M
Enterprise Value-29.73M

Share Statistics

Keros Therapeutics, Inc. currently has 19.83M shares outstanding.

Shares Outstanding19.83M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Keros Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 18.67. The price-to-sales ratio is 19.11, and the price-to-book ratio stands at 0.81.

PE Ratio18.67
PS Ratio19.11
PB Ratio0.81
P/TBV Ratio0.81
P/FCF Ratio-6.04
P/OCF Ratio-5.98

Enterprise Valuation

On an enterprise value basis, Keros Therapeutics, Inc. trades at an EV/EBITDA multiple of 1.84 and an EV/FCF ratio of 1.17. The EV/Sales ratio of 0.52 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 1.89 provides insight into valuation relative to core operating earnings.

EV / Sales0.52
EV / EBITDA1.84
EV / EBIT1.89
EV / FCF1.17

Financial Position

Keros Therapeutics, Inc. maintains a current ratio of 21.96, meaning it holds 22.0x the short-term assets needed to cover near-term liabilities.

Current Ratio21.96
Quick Ratio21.42
Debt / Equity5.99
Debt / EBITDA-0.16
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)-17.16
Return on Assets (ROA)-15.92
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Income Tax-2.94M
Effective Tax RateN/A

Stock Price Statistics

Keros Therapeutics, Inc.'s stock has declined approximately -25.47729% over the past 52 weeks. The 50-day moving average sits at 11.16, while the 200-day moving average is 12.40.

Beta (5Y)N/A
52-Week Price Change-25.47729%
50-Day Moving Average11.16
200-Day Moving Average12.40
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Keros Therapeutics, Inc. generated 15.01M in revenue and converted that into -83.16M in net income, yielding earnings per share of -3.10. EBITDA reached -99.87M, while operating income came in at -101.47M.

Revenue15.01M
Gross ProfitN/A
Operating Income-101.47M
Pretax Income-86.10M
Net Income-83.16M
EBITDA-99.87M
EBIT-101.47M
Earnings Per Share (EPS)-3.10

Balance Sheet

Keros Therapeutics, Inc. holds 257.61M in cash and equivalents against 15.72M in total debt, resulting in a net debt position of -257.61M. Total book value stands at 262.32M, with working capital of 254.73M providing operational flexibility.

Cash & Cash Equivalents257.61M
Total Debt15.72M
Net Debt-257.61M
Equity (Book Value)262.32M
Book Value Per Share13.23
Working Capital254.73M

Cash Flow

Keros Therapeutics, Inc. produced -47.99M in operating cash flow over the past twelve months. After subtracting -494,000.00 in capital expenditures, free cash flow totaled -48.49M - equivalent to -1.81 per share.

Operating Cash Flow-47.99M
Capital Expenditures-494,000.00
Free Cash Flow-48.49M
FCF Per Share-1.81

Margins

Keros Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -675.82 and net profit margin of -553.88 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin-675.82
Pretax Margin-573.44
Profit Margin-553.88
EBITDA Margin-665.17

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield181.06
FCF Yield-16.56

Scores

Keros Therapeutics, Inc. posts an Altman Z-Score of 2.39, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.39